AI 聊天
Loading data for LONN.SW — first visit, this takes a few seconds.

Lonza Group AG

LONN.SW · Swiss · USD

579.40 +1.60 (0.28%)

收盤價: Sep 11, 2026, 3:30 PM

市值
$37.10B
成交量
23.9K
下次財報日期
Jan 28, 2027

Lonza Group AG(LONN.SW)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →
營收 (ttm)
CHF 6.87B
淨利(ttm)
CHF 1.08B

正在載入...

最新財報

已通報較預期YoY 變更
營收n/an/a
EPSCHF 0,74-CHF 0,92n/a

下次財報

盤中。

估計 · 升級 →

查看財報詳情 →

指標

買價
579
市值
37.1B
淨利(ttm)
1.08B
0.84
15.51
34.25
24.08
P/B (ttm)
4.56
P/S (ttm)
5.40
財報日期
Jan 28, 2027
賣價
579.4
成交量
23,856
20 日平均成交量
141,058
開盤價
578.00
前收盤價
577.80
當日區間
576.00 - 583.20
52 週範圍
454.60 - 597.80
股利
$5.00 (0.93%)
除息日
May 12, 2026

關於 Lonza Group AG

查看公司資料 →
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland. Diagnostics & Research · Healthcare

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

類股 Healthcare
IPO 日期 Nov 1, 1999
員工 20,141
證券交易所 Swiss
股票代號 LONN.SW